Allergy Therapeutics Progressive development across portfolio

Hardman & Co Report Report DownloadsAllergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a ‘Named Patient’ basis. Trials to obtain full approval as a biological have progressed well in EU with the first patient recruited in the pivotal birch pollen allergy vaccine Phase III trial. US trials are back on-track with a new safety trial underway. A Phase I study of Acarovac MPL, a ‘dust mite allergy’ vaccine, has been approved in Spain for 32 patients. Finally, Polyvac Peanut has completed pre-clinical testing and has potential to significantly disrupt the peanut allergy market.

 

Sales: Underlying sales were strong during H1’17, with +18% CER growth to £34.2m. Sales were greatly strengthened on translation to £40.4m since >94% of the company’s sales are generated in mainland Europe. In Europe, AGY’s market share has reached 13%, whilst its global market share is up to 8.2%.

Clinical development: AGY announced three significant updates to its clinical-stage therapies this period. Notable was the first recruitment to the Phase III trial of the birch allergy therapy in EU, the first Pollinex Quattro candidate to enter Phase III, and also CTA approval of the first clinical trial of Acarovac.

R&D: AGY continues to invest in pre-clinical research alongside its clinical stage portfolio. Research is underway to explore the application of proprietary adjuvant technologies to infectious disease vaccines, including malaria. For Polyvac Peanut, positive efficacy and safety data were reported in a proof-of-concept study.

Forecasts: Our forecasts for the full year have not changed; they were last altered following the Jan’17 trading update. Total R&D investment is forecast to accelerate in 2H’17 and rise further when the larger US trials get underway in fiscal 2018. The ongoing EU trials are less expensive relative to US trials.

Investment summary: It is an exciting time for Allergy Therapeutics Plc, which is gaining market share for its Pollinex franchise in Europe and which is investing heavily in clinical development to achieve full Pollinex Quattro EU registration. The planned route into the US is back on track following FDA discussions. Read out from the EU Phase III PQBirch trial in 2018 will provide the next major value inflection point.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Hardman & Co

More articles like this

Allergens dominate UK food recalls, finds study

More than half of food recalls in the United Kingdom over a 5-year period were due to allergens, according to a recently released study. Allergen-related recalls increased annually until 2019, peaking at 118 before decreasing to

Allergy Therapeutics welcomes new Non-Executive Directors

Allergy Therapeutics announced the appointments of Anthony Parker and Simon Shen to its Board as Non-Executive Directors effective immediately. “I would like to welcome Anthony and Simon. Southern Fox and ZQ Capital have been long-standing and supportive shareholders of Allergy

Allergy Therapeutics updates on its clinical programmes

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that the first subject has been dosed in the pivotal Phase III G306 trial, to evaluate the efficacy and safety of

Allergy Therapeutics appoints two Non-Executive Directors

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of the Company, with immediate effect. Anthony represents

Allergies and Thanksgiving

As Thanksgiving and other holiday celebrations bring people around the table, Intermountain Healthcare dietitians say it’s crucial to take food allergies into consideration when planning the big meal. “A response to an allergic reaction can be

Allergy Therapeutics appoints Martin Hopcroft as interim CFO

Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO). Martin will report into Chief Executive

Food business operator fined for allergy breach

A food business operator based in Newcastle, England has been fined in court after serving a dish containing peanuts to a woman with a peanut allergy, resulting in her being hospitalised. According to the Food Standards

Are restaurants taking allergies seriously?

In an engaging panel held at Twickenham Stadium as part of New Food’s Food Safety Conference 2022, experts came together to debate whether food allergy regulations in restaurants are sufficient. Here’s the highlights. Are restaurant allergy

Allergy Therapeutics Subscription to raise £7 million

Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, today announces a conditional Subscription by the Subscribers, Southern Fox and ZQ Capital (acting through its affiliate SkyGem), to raise £7 million